| Dr Beata Elzbieta Dizoglio, MD | |
|
695 Eddy St, Suite 21, Providence, RI 02903-4941 | |
| (401) 272-1550 | |
| (401) 421-8792 |
| Full Name | Dr Beata Elzbieta Dizoglio |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 21 Years |
| Location | 695 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558581165 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD12267 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Women & Infants Hospital Of Rhode Island | Providence, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern New England Healthcare For Women, Llc | 0042486649 | 32 |
News Archive
Adjustment and testing of lab balances can be an arduous task. Difficulties are found not only the execution of procedures, but also in the possibility of misreading numbers when choosing and using weights.
A new resource captures more than 100 health insurance programs designed for low-income populations in developing countries —an important milestone in developing a comprehensive database of this emerging industry.
Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
Adjustment and testing of lab balances can be an arduous task. Difficulties are found not only the execution of procedures, but also in the possibility of misreading numbers when choosing and using weights.
A new resource captures more than 100 health insurance programs designed for low-income populations in developing countries —an important milestone in developing a comprehensive database of this emerging industry.
Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
| Entity Name | Southern New England Healthcare For Women, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699058826 PECOS PAC ID: 0042486649 Enrollment ID: O20120103000614 |
News Archive
Adjustment and testing of lab balances can be an arduous task. Difficulties are found not only the execution of procedures, but also in the possibility of misreading numbers when choosing and using weights.
A new resource captures more than 100 health insurance programs designed for low-income populations in developing countries —an important milestone in developing a comprehensive database of this emerging industry.
Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Beata Elzbieta Dizoglio, MD 695 Eddy Street, Suite 21, Providence, RI 02903 Ph: (401) 272-1550 | Dr Beata Elzbieta Dizoglio, MD 695 Eddy St, Suite 21, Providence, RI 02903-4941 Ph: (401) 272-1550 |
News Archive
Adjustment and testing of lab balances can be an arduous task. Difficulties are found not only the execution of procedures, but also in the possibility of misreading numbers when choosing and using weights.
A new resource captures more than 100 health insurance programs designed for low-income populations in developing countries —an important milestone in developing a comprehensive database of this emerging industry.
Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).
Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
› Verified 1 days ago
Donald Ramos, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 695 Eddy St, Providence, RI 02903 Phone: 401-272-1550 Fax: 401-421-8792 | |
Brittany S Hampton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1100 | |
Dr. Jane R. Sharp, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 297 Promenade St, Providence, RI 02908 Phone: 401-490-6464 | |
Dr. Katharine D Wenstrom, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 101 Dudley Street, 3rd Floor, Women & Infants Hospital Of Rhode Island/mfm Division, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7622 | |
Rebecca Crichton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 | |
Heather A Smith, MD, MPH Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 | |
Meena Theva, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 |